These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 23130761

  • 21. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.
    McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J.
    Lancet; 2010 Oct 16; 376(9749):1329-37. PubMed ID: 20851460
    [Abstract] [Full Text] [Related]

  • 22. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.
    Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L, HIV Prevention Trials Network (HPTN) 035 Study Team.
    AIDS; 2011 Apr 24; 25(7):957-66. PubMed ID: 21330907
    [Abstract] [Full Text] [Related]

  • 23. Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda.
    Cox AP, Foss AM, Shafer LA, Nsubuga RN, Vickerman P, Hayes RJ, Watts C, White RG.
    Sex Transm Infect; 2011 Dec 24; 87(7):635-9. PubMed ID: 21768615
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.
    Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M, COL-1492 Study Group.
    Lancet; 2002 Sep 28; 360(9338):971-7. PubMed ID: 12383665
    [Abstract] [Full Text] [Related]

  • 25. Women's interest in vaginal microbicides.
    Darroch JE, Frost JJ.
    Fam Plann Perspect; 1999 Sep 28; 31(1):16-23. PubMed ID: 10029928
    [Abstract] [Full Text] [Related]

  • 26. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection.
    Ng BE, Butler LM, Horvath T, Rutherford GW.
    Cochrane Database Syst Rev; 2011 Mar 16; (3):CD001220. PubMed ID: 21412869
    [Abstract] [Full Text] [Related]

  • 27. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
    Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.
    Trials; 2011 Mar 07; 12():67. PubMed ID: 21385354
    [Abstract] [Full Text] [Related]

  • 28. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F, Ruiz-Caro R, Veiga-Ochoa MD.
    Drug Des Devel Ther; 2017 Mar 07; 11():1767-1787. PubMed ID: 28670111
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.
    Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P.
    Lancet; 2008 Dec 06; 372(9654):1977-87. PubMed ID: 19059048
    [Abstract] [Full Text] [Related]

  • 30. Barrier contraceptive use and HIV infection among high-risk women in Cameroon.
    Zekeng L, Feldblum PJ, Oliver RM, Kaptue L.
    AIDS; 1993 May 06; 7(5):725-31. PubMed ID: 8391273
    [Abstract] [Full Text] [Related]

  • 31. To tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa.
    Kelly CA, Friedland BA, Morar NS, Katzen LL, Ramjee G, Mokgatle MM, Ahmed K.
    Cult Health Sex; 2015 May 06; 17(8):1004-20. PubMed ID: 25913101
    [Abstract] [Full Text] [Related]

  • 32. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.
    Roberts L, Liebenberg L, Barnabas S, Passmore JA.
    Best Pract Res Clin Obstet Gynaecol; 2012 Aug 06; 26(4):441-9. PubMed ID: 22429786
    [Abstract] [Full Text] [Related]

  • 33. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men.
    Wilkinson D, Ramjee G, Tholandi M, Rutherford G.
    Cochrane Database Syst Rev; 2002 Aug 06; (4):CD003939. PubMed ID: 12519623
    [Abstract] [Full Text] [Related]

  • 34. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.
    Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH, Mock PA, Siraprapasiri T, Friedland BA, Kilmarx PH, Markowitz LE.
    PLoS One; 2011 Aug 06; 6(9):e14831. PubMed ID: 21915249
    [Abstract] [Full Text] [Related]

  • 35. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
    Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, Morar N, Maslankowski L, Profy AT, Kelly C, Abdool Karim SS, Mayer KH.
    J Womens Health (Larchmt); 2003 Sep 06; 12(7):655-66. PubMed ID: 14583106
    [Abstract] [Full Text] [Related]

  • 36. Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection.
    Wiysonge CS, Shey M, Kongnyuy EJ, Sterne JA, Brocklehurst P.
    Cochrane Database Syst Rev; 2011 Jan 19; (1):CD003648. PubMed ID: 21249656
    [Abstract] [Full Text] [Related]

  • 37. Enrollment of adolescents aged 16-17 years old in microbicide trials: an evidence-based approach.
    Schenk KD, Friedland BA, Chau M, Stoner M, Plagianos MG, Skoler-Karpoff S, Palanee T, Ahmed K, Rathlagana MJ, Mthembu PN, Ngcozela N.
    J Adolesc Health; 2014 Jun 19; 54(6):654-62. PubMed ID: 24690188
    [Abstract] [Full Text] [Related]

  • 38. Educating men about vaginal microbicides: considerations from Kenya.
    Gitome SW, Kwena ZA, Harper CC, Cohen CR, Bukusi EA.
    Cult Health Sex; 2020 Jun 19; 22(6):660-674. PubMed ID: 31241426
    [Abstract] [Full Text] [Related]

  • 39.
    Henderson JT, Henninger M, Bean SI, Senger CA, Redmond N, O’Connor EA.
    ; 2020 08 19. PubMed ID: 32970399
    [Abstract] [Full Text] [Related]

  • 40. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group.
    Science; 2010 Sep 03; 329(5996):1168-74. PubMed ID: 20643915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.